Royce & Associates LP Buys 191,799 Shares of Stevanato Group S.p.A. $STVN

Royce & Associates LP boosted its stake in Stevanato Group S.p.A. (NYSE:STVN) by 63.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 493,023 shares of the company’s stock after acquiring an additional 191,799 shares during the quarter. Royce & Associates LP’s holdings in Stevanato Group were worth $9,920,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in STVN. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Stevanato Group in the 4th quarter valued at $9,269,000. Credit Agricole S A bought a new stake in Stevanato Group in the 3rd quarter valued at $9,785,000. TimesSquare Capital Management LLC lifted its position in Stevanato Group by 7.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 3,500,321 shares of the company’s stock valued at $70,426,000 after acquiring an additional 232,645 shares in the last quarter. Jennison Associates LLC lifted its position in Stevanato Group by 13.7% in the 4th quarter. Jennison Associates LLC now owns 1,772,896 shares of the company’s stock valued at $35,671,000 after acquiring an additional 213,602 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in Stevanato Group by 98.1% in the 3rd quarter. Bank of America Corp DE now owns 430,761 shares of the company’s stock valued at $11,092,000 after acquiring an additional 213,340 shares in the last quarter.

Stevanato Group Price Performance

STVN stock opened at €18.13 on Thursday. The company has a 50 day simple moving average of €15.87 and a 200 day simple moving average of €17.99. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of 30.73, a P/E/G ratio of 1.66 and a beta of 0.75. Stevanato Group S.p.A. has a 1 year low of €12.89 and a 1 year high of €28.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.63 and a quick ratio of 1.11.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings results on Friday, May 8th. The company reported €0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of €0.12 by (€0.01). Stevanato Group had a net margin of 11.76% and a return on equity of 10.27%. The business had revenue of €273.57 million during the quarter. During the same period in the prior year, the business posted $0.10 EPS. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. Research analysts anticipate that Stevanato Group S.p.A. will post 0.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

STVN has been the topic of several research reports. Jefferies Financial Group set a $17.50 price objective on shares of Stevanato Group in a research report on Tuesday, February 10th. Weiss Ratings lowered shares of Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 11th. Morgan Stanley lowered their price target on shares of Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating on the stock in a research note on Friday, March 6th. KeyCorp lowered their price target on shares of Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Finally, Wall Street Zen lowered shares of Stevanato Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Stevanato Group currently has an average rating of “Hold”.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.